The arbiter of medical regulations in the US is asking for public input on the international drug scheduling of marijuana following a request from the World Health Organization (WHO).

The US Food and Drug Administration (FDA) launched an initiative online on Monday (April 9) encouraging feedback on the status of cannabis, its medical benefits and potential abuse risks following a WHO request.

According to the US federal agency, the feedback on cannabis will be used to prepare a response for the WHO about abuse liability and diversion of the researched drugs. The FDA indicated in the document that it will accept comments until April 23.

At the time of publication, the request has received 959 comments. The three highlighted comments on the web page all support the removal of cannabis as a controlled substance.

“End the silly and outdated policy of restricting [cannabis]” one of the comments indicated. One commentator named Jim Barry, 45, said cannabis has helped him deal with bipolar and depression syndromes.

WHO on path to investigate medical benefits of cannabis

The actual call for comment from the agency is related to the “abuse potential, actual abuse, medical usefulness, trafficking, and impact of scheduling changes on availability for medical use of five drug substances,” according to the document.

These specified substances are: cannabis plant and resin, extracts and tinctures of Cannabis, Delta-9-Tetrahydrocannabinol (THC), stereoisomers of tetrahydrocannabinol and cannabidiol (CBD).

The FDA document alleges WHO will hold a special committee meeting in order to review the standing of the mentioned substances later this year during the 40th Expert Committee on Drug Dependence (ECDD).

The document notes in a previous meeting that WHO acknowledged the increase in cannabis use for medical purposes among patients, as well as for therapeutic use.

The organization noted that the categories of information for evaluating substances in pre-reviews are identical to those used in critical reviews and that the pre-review is a preliminary analysis, and findings should not determine whether the control status of a substance should be changed.

The Committee also noted an increase in the use of cannabis and its components for medical purposes and the emergence of new cannabis-related pharmaceutical preparations for therapeutic use.

Given the current state of cannabis as a controlled Schedule I substance under the Controlled Substances Act (CSA). Effectively placing cannabis as an illegal substance on a federal level in the U.S. Despite this, several states have changed their laws, legalizing marijuana.

As research for CBD and other cannabis compounds increases a clash of policy and reality takes place in the US, organizations have started studies to develop the potential of the federally illegal drug.

FDA to follow procedure but won’t recommend changes to the status of cannabis

In the FDA document, it is acknowledged “CBD-containing products are in human clinical testing in several therapeutic areas.” However, none of these products have marketing approval from the agency.

Despite the federal agency’s request for comments on cannabis, the U.S. Department of Health and Human Services (HHS) said it will not provide any recommendations on the “status of international control” for cannabis, or the other related substances.

“Instead, HHS will defer such consideration until WHO has made official recommendations to the Commission on Narcotic Drugs, which are expected to be made in mid-2018,” the document from the FDA indicated.

Last year deputy commissioner for policy, planning, legislation, and analysis for the FDA Anna K. Abram sent a notice requesting comments on the benefits of CBD alongside other substances. “CBD has been shown to be beneficial in experimental models of several neurological disorders, including those of seizure and epilepsy,” the document indicated.

Investor takeaway

Despite the intentions behind this request relating to WHO, it is still important to note the worldwide changes in cannabis outlook and policy are catching up with medical agencies.

Investors should be aware of the potential for any changes in the status of cannabis-based on recommendations from an international medical agency.

Don’t forget to follow us @INN_Cannabis for real-time news updates!

Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.

Trulieve to donate $20,000 in scholarship funding and $15,000 to support leadership development

Trulieve Cannabis Corp . (CSE: TRUL) (OTC: TCNNF), a leading and top-performing cannabis company in the United States today announced a new partnership with the Thurgood Marshall College Fund (TMCF), the nation’s largest organization exclusively representing the Black College Community. Trulieve will donate $20,000 to help fund several college scholarships awarded to students who are attending one of the organization’s member-schools as part of Trulieve’s diversity, equity, and inclusion initiatives. The $15,000 in talent funding is earmarked to support TMCF’s internship program, reaching a diverse talent pool of students and alumni from their 47 member-schools to provide immersive experiences at Trulieve.

Keep reading... Show less

The new dispensary expands patient access to Florida’s largest inventory of medical cannabis products

Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF) (“Trulieve” or “the Company”), a leading and top-performing cannabis company based in the United States announced today the opening of a brand-new Florida dispensary, the Company’s 80th nationwide. The new location marks the Company’s first in Tamarac and third in Broward County expanding patient access to Florida’s largest and broadest assortment of high-quality medical cannabis products.

Keep reading... Show less

Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce an update on the Company’s U.S. Food & Drug Administration (“FDA”) Phase 3 clinical trial (the “Study”) to evaluate the safety and efficacy of Bucillamine in patients with mild to moderate COVID-19.

With its recent $23 million dollar financing, the Company plans to aggressively expand from 14 clinical sites to up to 50 clinical sites to meet the next enrollment goals for the Study in Q2-2020. The Study is a randomized, double-blinded, placebo-controlled trial and the safety and efficacy data analyzed at each interim analysis timepoint of 210, 400, 600 and 800 completed patients are only made available to the Independent Data and Safety Monitoring Board (“DSMB”) for review and recommendations on continuation, stopping or changes to the conduct of the Study. In the event of any serious safety concerns, the DSMB would be notified to determine any risks and provide its recommendations. To date, in this initial 210 interim point there have been no serious safety concerns that required the DSMB to be notified.

Keep reading... Show less

HempFusion Wellness Inc. (TSX:CBD.U) (OTCQX:CBDHF) (FWB:8OO) (“HempFusion” or the “Company”), a leading health and wellness CBD company utilizing the power of whole-food hemp nutrition, is pleased to announce that its common shares have been approved for DTC full-service eligibility in the United States by the Depository Trust Company (“DTC”) and can now be both traded and serviced through DTC’s electronic book-entry system.

DTC is a subsidiary of the Depository Trust & Clearing Corp. (“DTCC”) that provides clearing and settlement services for the financial markets and settles the majority of securities transactions in the United States. This electronic method of clearing securities speeds up the receipt of stock and cash and thus accelerates the settlement process for investors and brokers, enabling the stock to be traded over a much wider selection of brokerage firms.

Keep reading... Show less

CFN Enterprises Inc. (OTCQB: CNFN) (CFN Media) partners with FMW Media Works LLC to produce a regular series on the global cannabis markets to air on major financial news networks across the US. Initial segment features leading cannabis analyst and US Multi-State Operator (MSO)

CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the leading media network dedicated to the global legal cannabis, CBD and psychedelics industries, today announced that its inaugural news segment on the cannabis markets, “Cannabis Market Outlook for 2021,” will air on Bloomberg, Newsmax and Fox Business.

Keep reading... Show less